Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes.
about
Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care: a systematic review.Performance and logistical challenges of alternative HIV-1 virological monitoring options in a clinical setting of Harare, Zimbabwe.Short communication: prospective comparison of qualitative versus quantitative polymerase chain reaction for monitoring virologic treatment failure in HIV-infected patients.Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana.Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting.Clinical evaluation of a low cost, in-house developed real-time RT-PCR human immunodeficiency virus type 1 (HIV-1) quantitation assay for HIV-1 infected patients.High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in GhanaEmerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Treatment switching in South Indian patients on HAART: what are the predictors and consequences?High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic: A cross-sectionChallenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.Programmatic and ethical challenges in the implementation of treatment-as-prevention in the context of HIV and drug-resistant tuberculosis co-infection in sub-Saharan Africa.Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania.
P2860
Q30238931-0CEDBCCA-5172-4FC6-A599-C63E0CB34285Q33849840-14F96858-45C5-4F22-B690-86C419C6B2A0Q33988234-4B7C6211-1BFF-4A31-840B-D8A10DFCC6DAQ34353431-E70390F6-A992-4633-8EB3-0E20A6A8A112Q35015853-8578278B-8168-4756-A4C5-F3F089DB7475Q35019884-E697E579-9E28-4C8D-98D7-A98802C94095Q35112701-F7DAE580-764D-411E-AAD6-E3418D28C2B0Q35119753-55557599-E182-41E8-B5CF-E04DF0A5D0F6Q35770848-BFB824B4-49B2-4F6C-8A84-0D6E54EABB10Q35914071-E79D7162-25DF-4978-9828-449C960254AAQ36669337-CA2428A9-7EA1-421A-9556-E33184E2BA83Q36787819-C27DBED4-7623-4431-855F-9ACC28CDD905Q37696892-3B56EADA-8E48-4477-91A8-8DE56BA28B84Q37955946-5BB4FDD6-9677-4F63-A108-522AD552783EQ38393167-BFA6BB7D-25DF-4013-9FD0-E4A79651F01EQ42232189-11B7AD88-B9DD-4533-85E9-64D3F0B22C80Q43940315-8FA1B505-4AA5-4010-8826-A65C72E99D35
P2860
Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Monitoring HIV antiretroviral ...... time to avoid costly outcomes.
@en
Monitoring HIV antiretroviral ...... time to avoid costly outcomes.
@nl
type
label
Monitoring HIV antiretroviral ...... time to avoid costly outcomes.
@en
Monitoring HIV antiretroviral ...... time to avoid costly outcomes.
@nl
prefLabel
Monitoring HIV antiretroviral ...... time to avoid costly outcomes.
@en
Monitoring HIV antiretroviral ...... time to avoid costly outcomes.
@nl
P356
P1476
Monitoring HIV antiretroviral ...... time to avoid costly outcomes.
@en
P2093
Frederick K Sawe
James A McIntyre
P304
P356
10.1086/600397
P407
P577
2009-08-01T00:00:00Z